Research Article

Intraocular Foreign Bodies: Clinical Characteristics and Prognostic Factors Influencing Visual Outcome and Globe Survival in 373 Eyes

Table 3

Univariate analysis on features of eyes with IOFBs affecting BCVA (BCVA <1.3 logMAR and BCVA ≥0.5 logMAR).

VariablesBCVA valueBCVA value
<1.3 logMAR
no. (%)
≥1.3 logMAR
no. (%)
<0.5 logMAR
no. (%)
≥0.5 logMAR
no. (%)

Age (years)
 <187 (35.0)13 (65.0)0.0208 (40.0)12 (60.0)0.002
 18∼50101 (36.5)176 (63.5)169 (61.0)108 (39.0)
 ≥5041 (53.9)35 (46.1)59 (77.6)17 (22.4)

Presenting VA
 <0.5 logMAR140 (50.0)140 (50.0)<0.001221 (78.9)59 (21.1)<0.001
 ≥0.5 logMAR9 (9.7)84 (90.3)15 (16.1)78 (83.9)

Length of wound
 0∼4 mm77 (32.4)161 (67.6)<0.001126 (52.9)112 (47.1)<0.001
 4∼10 mm52 (49.5)53 (50.5)85 (81.0)20 (19.0)
 10 mm or longer20 (66.7)10 (33.3)25 (83.3)5 (16.7)

Entry site of IOFBs
 I zone108 (38.8)170 (61.2)0.395172 (61.9)106 (38.1)0.612
 II zone31 (47.0)35 (53.0)45 (68.2)21 (31.8)
 III zone10 (34.5)19 (65.5)19 (65.5)10 (34.5)

Time before primary repair
 Self-sealing37 (27.6)97 (72.4)0.00168 (50.7)66 (49.3)<0.001
 <24 h95 (46.1)111 (53.9)141 (68.4)65 (31.6)
 ≥24 h17 (51.5)16 (48.5)27 (81.8)6 (18.2)

Surface of IOFBs
 Small: <4 mm215 (30.0)35 (70.0)<0.00124 (48.0)26 (52.0)<0.001
 Medium: 4∼16 mm2103 (36.3)181 (63.7)176 (62.0)108 (38.0)
 Large: >16 mm231 (79.5)8 (20.5)36 (92.3)3 (7.7)

Multiple IOFBs
 Yes15 (57.7)11 (42.3)0.05519 (73.1)7 (26.9)0.282
 No134 (38.6)213 (61.4)217 (62.5)130 (37.5)

Magnetic of IOFBs
 Yes118 (37.3)198 (62.7)0.016193 (61.1)123 (38.9)0.038
 No31 (54.4)26 (45.6)43 (75.4)14 (24.6)

Location of IOFBs
 Anterior chamber12 (25.0)36 (75.0)0.00122 (45.8)26 (54.2)<0.001
 Intralens6 (22.2)21 (77.8)9 (33.3)18 (66.7)
 Ciliary body12 (66.7)6 (33.3)15 (83.3)3 (16.7)
 Vitreous59 (36.9)101 (63.1)102 (63.7)58 (36.3)
 Retina60 (50.0)60 (50.0)88 (73.3)32 (26.7)

Time before IOFBs removal
 Within 24 h77 (38.3)124 (61.7)0.675122 (60.7)79 (39.3)0.427
 24∼72 h30 (43.5)39 (56.5)51 (73.9)18 (26.1)
 72 h∼1 week20 (47.6)22 (52.4)25 (59.5)17 (40.5)
 1∼2 weeks6 (28.6)15 (71.4)14 (66.7)7 (33.3)
 2 weeks∼1 month9 (45.0)11 (55.0)13 (65.0)7 (35.0)
 3 months or longer7 (35.0)13 (65.0)11 (55.0)9 (45.0)

Cataract
 Yes128 (42.0)177 (58.0)0.091205 (67.2)100 (32.8)0.001
 No21 (30.9)47 (69.1)31 (45.6)37 (54.4)

Vitreous hemorrhage
 Yes90 (51.7)84 (48.3)<0.001138 (79.3)36 (20.7)<0.001
 No59 (29.6)140 (70.4)98 (49.2)101 (50.8)

Retinal breaks
 Yes70 (57.9)51 (42.1)<0.001100 (82.6)21 (17.4)<0.001
 No79 (31.3)173 (68.7)136 (54.0)116 (46.0)

Retinal detachment
 Yes42 (59.2)29 (40.8)<0.00158 (81.7)13 (18.3)0.001
 No107 (35.4)195 (64.6)178 (58.9)124 (41.1)

PVR
 Yes34 (52.3)31 (47.7)0.02558 (89.2)7 (10.8)<0.001
 No115 (37.3)193 (62.7)178 (57.8)130 (42.2)
Endophthalmitis
 Yes34 (61.8)21 (38.2)<0.00147 (85.5)8 (14.5)0.001
 No115 (36.2)203 (63.8)189 (59.4)129 (40.6)

Surgery approaches
 Magnet50 (31.4)109 (68.6)0.00187 (54.7)72 (45.3)0.002
 Vitrectomy74 (51.4)70 (48.6)107 (74.3)37 (25.7)
 Forceps or phaco25 (35.7)45 (64.3)42 (60.0)28 (40.0)

Multiple surgeries
 Yes95 (46.1)111 (53.9)0.007153 (74.3)53 (25.7)<0.001
 No54 (32.3)113 (67.7)83 (49.7)84 (50.3)

Tamponade used
 Nonvitrectomy74 (32.3)155 (67.7)<0.001128 (55.9)101 (44.1)<0.001
 Gas implantation29 (70.7)12 (29.3)33 (80.5)8 (19.5)
 Silicone injection28 (50.9)27 (49.1)46 (83.6)9 (16.4)
 Balanced saline18 (37.5)30 (62.5)29 (60.4)19 (39.6)